How age affects the immune response to dengue virus after initial infection
Age in dengue antibody response and risk after primary natural infection
This study looks at how a child's age affects their immune response to the dengue virus after their first infection, helping us learn more about how to create better vaccines to protect kids from dengue.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10873882 on NIH RePORTER |
What this research studies
This research investigates how children's age influences their immune response to the dengue virus following their first natural infection. It aims to understand the production of antibodies that protect against different serotypes of the virus, which is crucial for developing effective vaccines. By studying children over time, the research will gather important data on how age impacts the durability and specificity of these protective antibodies. This information could lead to better vaccination strategies and improved outcomes for children at risk of dengue.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have experienced a primary natural infection with the dengue virus.
Not a fit: Patients who are older than 11 years or have not had a natural dengue infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and treatments for dengue, particularly for children.
How similar studies have performed: Previous research has shown that understanding immune responses in children can lead to significant advancements in vaccine development, indicating that this approach has potential for success.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Zhu, Deanna — Univ of North Carolina Chapel Hill
- Study coordinator: Zhu, Deanna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.